Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 300

The DOI matches its Crossref record; 232 of the 232 references it cites were found in a registry or an index.

Emerging therapies in Parkinson disease — repurposed drugs and new approaches

Open access
Elkouzi, Ahmad, Vedam-Mai, Vinata, Eisinger, Robert S., Okun, Michael S.·2019·Nature Reviews Neurology

Abstract

Parkinson disease (PD) treatment options have conventionally focused on dopamine replacement and provision of symptomatic relief. Current treatments cause undesirable adverse effects, and a large unmet clinical need remains for treatments that offer disease modification and that address symptoms resistant to levodopa. Advances in high-throughput drug screening methods for small molecules, developments in disease modelling and improvements in analytical technologies have collectively contributed to the emergence of novel compounds, repurposed drugs and new technologies. In this Review, we focus on disease-modifying and symptomatic therapies under development for PD. We review cellular therapies and repurposed drugs, such as nilotinib, inosine, isradipine, iron chelators and anti-inflammatories, and discuss how their success in preclinical models has paved the way for clinical trials. We provide an update on immunotherapies and vaccines. In addition, we review non-pharmacological interventions targeting motor symptoms, including gene therapy, adaptive deep brain stimulation (DBS) and optogenetically inspired DBS. Given the many clinical phenotypes of PD, individualization of therapy and precision of treatment are likely to become important in the future.Conventional therapies for Parkinson disease (PD) include dopamine replacement and therapies targeting symptomatic relief, but these approaches fail to modify the underlying disease. This Review explores the novel PD treatment strategies currently being investigated, including pharmaceuticals, cell therapies, immunotherapies, gene therapies and new technologies.Key pointsEmerging therapies for Parkinson disease (PD) have focused largely on disease modification and on dopamine resistance symptoms, which are both important unmet needs.Some new disease-modifying therapies target α-synuclein and its pathways, whereas others target different genes and proteins implicated in PD pathogenesis, including leucine-rich repeat kinase 2, parkin and glucocerebrosidase.Disease-modifying pharmacotherapies (such as nilotinib, inosine and isradipine) are being repurposed to treat PD; antibody therapies, vaccines and immune-mediated therapies that aim to clear abnormal proteins have also emerged as promising approaches.Cellular therapies can be divided into rescue and restoration therapies; rescue therapy aims to salvage neurons and slow the progression of the disease whereas restoration therapy focuses on replacing neurons.Adaptive deep brain stimulation is an alternative symptomatic therapy that can be used to target dopamine-responsive and dopamine-resistant symptoms.Current efforts to overcome challenges in therapeutic development have focused on individualization of therapy and precision in treatment; these principles are especially important given the heterogeneity of clinical PD subtypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41582-019-0155-7

Cites

232 of 232 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 232 references

Cited by

See all 300

Metadata

Authors
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S.
Venue
Nature Reviews Neurology
Published
2019-03-12
Volume
15
Issue
4
Pages
204-223
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W2921132745
Cited by
300
References
232
FWCI
7.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging therapies in Parkinson disease — repurposed drugs and new approaches. https://app.cochat.ai/papers/10.1038/s41582-019-0155-7
The paper
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019). Emerging therapies in Parkinson disease — repurposed drugs and new approaches. Nature Reviews Neurology. https://doi.org/10.1038/s41582-019-0155-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.